-
Article
Open AccessNarcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy
Narcolepsy type 1 (NT1) is caused by a loss of hypocretin/orexin transmission. Risk factors include pandemic 2009 H1N1 influenza A infection and immunization with Pandemrix®. Here, we dissect disease mechanism...
-
Article
Open AccessExploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learning
Narcolepsy is a rare life-long disease that exists in two forms, narcolepsy type-1 (NT1) or type-2 (NT2), but only NT1 is accepted as clearly defined entity. Both types of narcolepsies belong to the group of c...
-
Article
Open AccessHealth-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
The stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well tolerated treatment for the symptoms of attention-deficit/hyperactivity disorder (ADHD). Positive impacts of LDX on he...
-
Article
Pharmacological Management of Narcolepsy and Cataplexy in Pediatric Patients
Narcolepsy is a neurological disorder frequently occurring from childhood and persisting through adolescence and adulthood. Individuals suffering from narcolepsy exhibit excessive daytime somnolence, sleep att...
-
Article
Open AccessEfficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial
Lisdexamfetamine dimesylate (LDX) is a long-acting, prodrug stimulant therapy for patients with attention-deficit/hyperactivity disorder (ADHD). This randomized placebo-controlled trial of an optimized daily d...
-
Article
Open AccessHealth-Related Quality of Life and Functional Outcomes from a Randomized, Controlled Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention Deficit Hyperactivity Disorder
Optimal management of attention deficit hyperactivity disorder (ADHD) aims not only to ameliorate patients’ symptoms, but also to improve health-related quality of life (HRQL) and functioning. A pivotal, 7-wee...
-
Article
Open AccessA Post Hoc Comparison of the Effects of Lisdexamfetamine Dimesylate and Osmotic-Release Oral System Methylphenidate on Symptoms of Attention-Deficit Hyperactivity Disorder in Children and Adolescents
There are limited head-to-head data comparing the efficacy of long-acting amfetamine- and methylphenidate-based psychostimulants as treatments for individuals with attention-deficit hyperactivity disorder (ADH...
-
Article
Correction: Corrigendum: Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy
Nat. Genet. 42, 786–789 (2010); published online 15 August 2010; corrected after print 27 October 2010 In the version of this article initially published, the name of author Peter Vollenweider was incorrectly ...
-
Chapter
Treatment of Narcolepsy in Children
Narcolepsy is a chronic primary sleep-wake disorder, characterized by excessive daytime sleepiness (EDS), sudden sleep episodes, and attacks of muscle atonia mostly triggered by emotions (cataplexy). Narcoleps...
-
Article
Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy
Mehdi Tafti and colleagues identify new HLA class II haplotypes that are strongly protective against narcolepsy. Their analyses suggest a virtually causal role for the HLA region in determining narcolepsy susc...
